Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01868451 · ClinicalTrials.gov registry record · NA
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
A NA study of Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 118
- Enrollment target
- 10
- Study locations
NCT01868451 is a NA study of Hodgkin Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 118 participants, below the 164-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (28% lower). The trial reports 10 study locations across 3 states.
The verdict
NCT01868451, a NA study of Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 118 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to compare the outcomes across the 4 different treatment groups. The investigators hope that this treatment will improve the ability to cure more patients with HL and also limit the long-term side effects from the treatment. Although eliminating radiation in cohort 4 will eliminate the risk for long-term side effects from radiation, it is also possible that with BV+AVD chemotherapy alone there may be an increased risk of the Hodgkin lymphoma coming back after initial treatment.
Conditions Studied
Interventions
- DRUG Dacarbazine
- DRUG Brentuximab vedotin (SGN-35)
- DRUG Doxorubicin HCL
- DRUG Vinblastine Sulfate
- RADIATION Involved-Site Radiation Therapy (ISRT)
Study Locations (10)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester Medical Center - Rochester
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
California
- City of Hope - Duarte
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2013-05 |
| Est. Completion | 2026-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01868451
The ClinicalTrials.gov registry entry for NCT01868451 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (28% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Dacarbazine is the first listed.
NCT01868451 reports 10 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT01868451 about?
NCT01868451 is a clinical study titled "Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma". The purpose of this study is to compare the outcomes across the 4 different treatment groups. The investigators hope that this treatment will improve the ability to cure more patients with HL and also limit the long-term side effects from the treatment. Although eliminating radiation in cohort 4 wil...
What is the current status of trial NCT01868451?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 118 participants. The study started on 2013-05. Estimated completion is 2026-05.
What conditions does trial NCT01868451 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT01868451?
The interventions under investigation include: Dacarbazine (DRUG), Brentuximab vedotin (SGN-35) (DRUG), Doxorubicin HCL (DRUG), Vinblastine Sulfate (DRUG), Involved-Site Radiation Therapy (ISRT) (RADIATION).
Who is sponsoring clinical trial NCT01868451?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01868451 being conducted?
This trial has 10 study locations across California, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lifestyle Intervention of Food and Exercise for Lymphoma Survivors
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
-
Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
ACTIVE NOT RECRUITING · NA
-
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · NA
-
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.